Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to announce that it has entered into a Letter of Intent (“LOI”) with Immunova,

Shares of Portage Biotech Inc (PRTG) are up nearly 200% at $9.14 in premarket trading, following the announcement of a Letter of

Shares of Portage Biotech more than doubled after the company said it has entered into a letter of intent to sell one of its subsidiaries to Immunova. The stock was changing hands at $7.33 in early trading. Shares closed the market at $3.25 on Monday. The volatile stock is still down 80% since the start of the year.